Tuesday, June 12, 2007 1:02:29 PM
I saw on iHub that the advantage for the triple-therapy arm was over 10% :
http://www.investorshub.com/boards/read_msg.asp?message_id=20377556
But it actually did NOT make the cut, if you read the news release:
Of patients that completed 12 weeks of therapy, 72.2 percent .......triple combination therapy (arm B) achieved HCV PCR-negativity, compared to 61.5 percent ......There were three discontinuations from the study, all due to adverse events (AEs)...... valopicitabine-related gastrointestinal toxicity. The two other AEs, including a serious adverse event (SAE).....occurred in the triple combination arm (arm B).
That checks out @ 3 patients left out who did not make the grade; instead of 72.2% of 36 on triple (exactly 26 of course), it's 26/39 which is 66.66 %. Compare that with 24/39 on SoC. Is there an investment thesis here ?
So the margin is 5.5% not 10%. Almost certainly NOT statistically significant. Actually using Fischer's Exact Test the result is:
"The two-tailed P value equals 0.8137"
Plus all the discontinuations were due to AEs on this "efficaceous" arm.
Sooner or later people (analysts etc) will see through this release. I expect IDIX to drift lower now, it's too vulnerable.
"....on the biotech battle-field, you need some élan...."
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM
ECGI Holdings Accelerates Strategic Initiatives by Securing First of Two $125,000 Convertible Notes • ECGI • Jun 4, 2024 12:15 PM